CXCR4 inhibition is also shown to increase tumor-infiltrating T cells and decrease immunosuppressive MDSCs in preclinical findings, and results in sensitization of tumors to the chemotherapy agents of cisplatin, paclitaxel, and gemcitabine (Xun et al., 2020). This evidence concerns the gene CXCR4 and neoplasm.